Last reviewed · How we verify

NCT05198128

Ovarian Hyperstimulation Syndrome Using Calcium Infusion

Status unknown NA Last updated 22 February 2022
What this trial tests

NA trial testing Calcium intravenous infsuion in Ovarian Hyperstimulation Syndrome in 200 participants. Status unknown.

Timeline
1 March 2022
Primary endpoint
25 April 2023
10 May 2023

Quick facts

Lead sponsorAl-Azhar University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment200
Start date1 March 2022
Primary completion25 April 2023
Estimated completion10 May 2023

Drugs / interventions tested

Conditions studied

Sponsor

Al-Azhar University

Who can join

Adults 18 to 45, female only, with Ovarian Hyperstimulation Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the incidence of OHSS and clinical outcomes after calcium IV infusion in high-risk women undergoing ART

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Al-Azhar University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05198128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing